We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.
- Authors
Ruan, Jia; Martin, Peter; Furman, Richard R; Lee, Shing M; Cheung, Ken; Vose, Julie M; Lacasce, Ann; Morrison, Julia; Elstrom, Rebecca; Ely, Scott; Chadburn, Amy; Cesarman, Ethel; Coleman, Morton; Leonard, John P
- Abstract
The proteasome inhibitor bortezomib may enhance activity of chemoimmunotherapy in lymphoma. We evaluated dose-escalated bortezomib plus standard cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus rituximab (R) in patients with diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL).
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Vol 29, Issue 6, p690
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2010.31.1142